Ziglip-M 50/850 Tablet is a combination oral antidiabetic medication containing Metformin 850 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily reduces hepatic glucose production and improves insulin sensitivity, thereby enhancing peripheral glucose uptake and utilization. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, prolongs the action of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner. The synergistic effect of these agents helps achieve better glycemic control by targeting multiple pathophysiological defects of type 2 diabetes. Ziglip-M 50/850 is typically prescribed when diet, exercise, and monotherapy with either agent do not provide adequate glycemic control. It is important to monitor renal function prior to and during therapy, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort, which often diminish with continued use. Hypoglycemia risk is low but may increase when combined with other antidiabetic agents. This medication should be used under medical supervision, with regular monitoring of blood glucose levels and adherence to lifestyle modifications.